Literature DB >> 16830265

Homozygosity for the double D409H+H255Q allele in type II Gaucher disease.

Helen Michelakakis1, Marina Moraitou, Evagelia Dimitriou, Raul Santamaria, Gessami Sanchez, Laura Gort, Amparo Chabas, Daniel Grinberg, Maria Dassopoulou, Spyros Fotopoulos, Lluisa Vilageliu.   

Abstract

Homozygosity for D409H has been associated with a unique type III subtype of the disease with a phenotype dominated by severe cardiovascular involvement, whereas neurological findings, if present, are restricted to oculomotor apraxia and features such as visceromegaly are either minimal or absent. Using PCR amplification followed by restriction enzyme analysis, 3 patients (1 Greek, 2 Albanians) were IDentified with the D409H/D409H genotype. All shared a very severe early-onset neurological phenotype that classified them as type II. Amplification and sequencing of the full coding region of the GBA gene revealed that all three patients were homozygous not only for D409H but also for H255Q. Both mutations were present on the same allele, as shown by analysis of the parental DNA. The double D409H+H255Q allele was found in heterozygosity in Greek, Bulgarian and Argentinian patients but was not IDentified in any Spanish patients carrying the D409H mutation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16830265     DOI: 10.1007/s10545-006-0316-x

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  9 in total

1.  Skin ultrastructural findings in type 2 Gaucher disease: diagnostic implications.

Authors:  Aegean Chan; Walter M Holleran; Tajh Ferguson; Debra Crumrine; Ozlem Goker-Alpan; Raphael Schiffmann; Nahid Tayebi; Edward I Ginns; Peter M Elias; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2011-09-16       Impact factor: 4.797

Review 2.  Neuropathic Gaucher disease.

Authors:  Gregory M Pastores
Journal:  Wien Med Wochenschr       Date:  2010-12

Review 3.  Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity.

Authors:  N Gupta; I M Oppenheim; E F Kauvar; N Tayebi; E Sidransky
Journal:  Blood Cells Mol Dis       Date:  2010-09-28       Impact factor: 3.039

4.  Gaucher disease in North Macedonia: Unexpected prevalence of the N370S GBA1 allele with attenuated disease expression.

Authors:  Nevenka Ridova; Sanja Trajkova; Biljana Chonevska; Zlate Stojanoski; Martin Ivanovski; Marija Popova-Labachevska; Simona Stojanovska-Jakimovska; Venko Filipche; Aspazija Sofijanova; Irina Panovska-Stavridis
Journal:  Mol Genet Metab Rep       Date:  2022-07-08

5.  Glucocerebrosidase mutation H255Q appears to be exclusively in cis with D409H: structural implications.

Authors:  J Vithayathil; G Gibney; A D Baxevanis; B K Stubblefield; E Sidransky; N Tayebi
Journal:  Clin Genet       Date:  2009-05       Impact factor: 4.438

Review 6.  Gaucher disease: Basic and translational science needs for more complete therapy and management.

Authors:  Gregory A Grabowski; Armand H M Antommaria; Edwin H Kolodny; Pramod K Mistry
Journal:  Mol Genet Metab       Date:  2020-12-29       Impact factor: 4.797

Review 7.  The Spectrum of Neurological Manifestations Associated with Gaucher Disease.

Authors:  Tamanna Roshan Lal; Ellen Sidransky
Journal:  Diseases       Date:  2017-03-02

8.  Gaucher disease: clinical phenotypes and refining GBA mutational spectrum in Thai patients.

Authors:  Tim Phetthong; Thipwimol Tim-Aroon; Arthaporn Khongkraparn; Saisuda Noojarern; Chulaluck Kuptanon; Khunton Wichajarn; Achara Sathienkijkanchai; Kanya Suphapeetiporn; Pimlak Charoenkwan; Adisak Tantiworawit; Naruwan Noentong; Duangrurdee Wattanasirichaigoon
Journal:  Orphanet J Rare Dis       Date:  2021-12-20       Impact factor: 4.123

Review 9.  Factors and processes modulating phenotypes in neuronopathic lysosomal storage diseases.

Authors:  Joanna Jakóbkiewicz-Banecka; Magdalena Gabig-Cimińska; Zyta Banecka-Majkutewicz; Bogdan Banecki; Alicja Węgrzyn; Grzegorz Węgrzyn
Journal:  Metab Brain Dis       Date:  2013-12-05       Impact factor: 3.584

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.